---
layout: default
title: Personalised Insulin Adjustment with Reinforcement Learning: An In-Silico Validation for People with Diabetes on Intensive Insulin Treatment
---

# Personalised Insulin Adjustment with Reinforcement Learning: An In-Silico Validation for People with Diabetes on Intensive Insulin Treatment

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2505.14477" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2505.14477v1</a>
  <a href="https://arxiv.org/pdf/2505.14477.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2505.14477v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2505.14477v1', 'Personalised Insulin Adjustment with Reinforcement Learning: An In-Silico Validation for People with Diabetes on Intensive Insulin Treatment')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Maria Panagiotou, Lorenzo Brigato, Vivien Streit, Amanda Hayoz, Stephan Proennecke, Stavros Athanasopoulos, Mikkel T. Olsen, Elizabeth J. den Brok, Cecilie H. Svensson, Konstantinos Makrilakis, Maria Xatzipsalti, Andriani Vazeou, Peter R. Mertens, Ulrik Pedersen-Bjergaard, Bastiaan E. de Galan, Stavroula Mougiakakou

**åˆ†ç±»**: cs.LG

**å‘å¸ƒæ—¥æœŸ**: 2025-05-20

**DOI**: [10.1109/ACCESS.2025.3600738](https://doi.org/10.1109/ACCESS.2025.3600738)

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºè‡ªé€‚åº”åŸºç¡€-æ³¢åŠ¨å‰‚é‡å»ºè®®ç³»ç»Ÿä»¥ä¼˜åŒ–ç³–å°¿ç—…æ‚£è€…èƒ°å²›ç´ è°ƒæ•´**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±äºŒï¼šRLç®—æ³•ä¸æ¶æ„ (RL & Architecture)**

**å…³é”®è¯**: `èƒ°å²›ç´ è°ƒæ•´` `å¼ºåŒ–å­¦ä¹ ` `ä¸ªæ€§åŒ–åŒ»ç–—` `ç³–å°¿ç—…ç®¡ç†` `è¡€ç³–æ§åˆ¶` `è‡ªæˆ‘ç›‘æµ‹` `åŸºç¡€-æ³¢åŠ¨å‰‚é‡å»ºè®®`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç°æœ‰çš„èƒ°å²›ç´ è°ƒæ•´æ–¹æ³•åœ¨åº”å¯¹1å‹å’Œé•¿æœŸ2å‹ç³–å°¿ç—…æ‚£è€…çš„ä¸ªä½“åŒ–éœ€æ±‚æ—¶å­˜åœ¨ä¸è¶³ï¼Œå¯¼è‡´è¡€ç³–æ§åˆ¶æ•ˆæœä¸ç†æƒ³ã€‚
2. æœ¬ç ”ç©¶æå‡ºäº†è‡ªé€‚åº”åŸºç¡€-æ³¢åŠ¨å‰‚é‡å»ºè®®ç³»ç»Ÿï¼ˆABBAï¼‰ï¼Œåˆ©ç”¨å¼ºåŒ–å­¦ä¹ ä¸ºæ‚£è€…æä¾›ä¸ªæ€§åŒ–çš„èƒ°å²›ç´ æ²»ç–—å»ºè®®ï¼Œæ—¨åœ¨æé«˜è¡€ç³–æ§åˆ¶çš„æ—¶é—´èŒƒå›´ã€‚
3. å®éªŒç»“æœè¡¨æ˜ï¼ŒABBAåœ¨æ¨¡æ‹Ÿæµ‹è¯•ä¸­æ˜¾è‘—æé«˜äº†è¡€ç³–æ§åˆ¶çš„æ—¶é—´èŒƒå›´ï¼Œå¹¶å‡å°‘äº†ä½äºå’Œé«˜äºç›®æ ‡èŒƒå›´çš„æ—¶é—´ï¼Œç›¸è¾ƒäºä¼ ç»Ÿæ–¹æ³•è¡¨ç°æ›´ä½³ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

å°½ç®¡èƒ°å²›ç´ åˆ¶å‰‚å’ŒæŠ€æœ¯æœ‰äº†æ˜¾è‘—è¿›å±•ï¼Œä½†å¯¹å¤§å¤šæ•°1å‹ç³–å°¿ç—…ï¼ˆT1Dï¼‰å’Œé•¿æœŸ2å‹ç³–å°¿ç—…ï¼ˆT2Dï¼‰æ‚£è€…è€Œè¨€ï¼Œèƒ°å²›ç´ è°ƒæ•´ä»ç„¶æ˜¯ä¸€ä¸ªæŒç»­çš„æŒ‘æˆ˜ã€‚æœ¬ç ”ç©¶æå‡ºäº†åŸºäºå¼ºåŒ–å­¦ä¹ çš„è‡ªé€‚åº”åŸºç¡€-æ³¢åŠ¨å‰‚é‡å»ºè®®ç³»ç»Ÿï¼ˆABBAï¼‰ï¼Œæ—¨åœ¨ä¸ºè¿›è¡Œè‡ªæˆ‘ç›‘æµ‹è¡€ç³–æµ‹é‡å’Œå¤šæ¬¡æ¯æ—¥èƒ°å²›ç´ æ³¨å°„çš„T1Då’ŒT2Dæ‚£è€…æä¾›ä¸ªæ€§åŒ–çš„èƒ°å²›ç´ æ²»ç–—å»ºè®®ã€‚é€šè¿‡ä¸æ ‡å‡†åŸºç¡€-æ³¢åŠ¨å‰‚é‡é¡¾é—®ï¼ˆBBAï¼‰è¿›è¡Œæ¯”è¾ƒï¼ŒABBAåœ¨æé«˜è¡€ç³–æ§åˆ¶çš„æ—¶é—´èŒƒå›´ï¼ˆTIRï¼‰æ–¹é¢è¡¨ç°å‡ºæ˜¾è‘—ä¼˜åŠ¿ã€‚æ¨¡æ‹Ÿå®éªŒæ˜¾ç¤ºï¼ŒABBAæ˜¾è‘—æ”¹å–„äº†TIRï¼Œå¹¶å‡å°‘äº†ä½äºå’Œé«˜äºèŒƒå›´çš„æ—¶é—´ã€‚ABBAçš„æ€§èƒ½åœ¨ä¸¤ä¸ªæœˆå†…æŒç»­æ”¹å–„ï¼Œè€ŒBBAä»…æœ‰å¾®å°å˜åŒ–ã€‚è¯¥ä¸ªæ€§åŒ–èƒ°å²›ç´ è°ƒæ•´æ–¹æ³•æœ‰æ½œåŠ›è¿›ä¸€æ­¥ä¼˜åŒ–è¡€ç³–æ§åˆ¶ï¼Œæ”¯æŒT1Då’ŒT2Dæ‚£è€…çš„æ—¥å¸¸è‡ªæˆ‘ç®¡ç†ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šæœ¬ç ”ç©¶æ—¨åœ¨è§£å†³1å‹å’Œé•¿æœŸ2å‹ç³–å°¿ç—…æ‚£è€…åœ¨èƒ°å²›ç´ è°ƒæ•´ä¸­çš„ä¸ªæ€§åŒ–éœ€æ±‚ä¸è¶³çš„é—®é¢˜ã€‚ç°æœ‰çš„æ ‡å‡†åŸºç¡€-æ³¢åŠ¨å‰‚é‡é¡¾é—®ï¼ˆBBAï¼‰åœ¨æä¾›ä¸ªæ€§åŒ–å»ºè®®æ—¶æ•ˆæœæœ‰é™ï¼Œå¯¼è‡´æ‚£è€…çš„è¡€ç³–æ§åˆ¶ä¸ç†æƒ³ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡æå‡ºçš„è‡ªé€‚åº”åŸºç¡€-æ³¢åŠ¨å‰‚é‡å»ºè®®ç³»ç»Ÿï¼ˆABBAï¼‰åŸºäºå¼ºåŒ–å­¦ä¹ ï¼Œé€šè¿‡åˆ†ææ‚£è€…çš„è¡€ç³–ç›‘æµ‹æ•°æ®ï¼ŒåŠ¨æ€è°ƒæ•´èƒ°å²›ç´ å‰‚é‡ï¼Œä»¥å®ç°æ›´å¥½çš„è¡€ç³–æ§åˆ¶æ•ˆæœã€‚è¯¥æ–¹æ³•çš„è®¾è®¡æ—¨åœ¨æé«˜ä¸ªä½“åŒ–æ²»ç–—çš„ç²¾å‡†åº¦å’Œæœ‰æ•ˆæ€§ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šABBAçš„æ•´ä½“æ¶æ„åŒ…æ‹¬æ•°æ®æ”¶é›†æ¨¡å—ã€å¼ºåŒ–å­¦ä¹ ç®—æ³•æ¨¡å—å’Œå†³ç­–æ”¯æŒæ¨¡å—ã€‚æ•°æ®æ”¶é›†æ¨¡å—è´Ÿè´£è·å–æ‚£è€…çš„è¡€ç³–ç›‘æµ‹æ•°æ®ï¼Œå¼ºåŒ–å­¦ä¹ ç®—æ³•æ¨¡å—åˆ™é€šè¿‡å†å²æ•°æ®è®­ç»ƒæ¨¡å‹ï¼Œæœ€åå†³ç­–æ”¯æŒæ¨¡å—æ ¹æ®æ¨¡å‹è¾“å‡ºä¸ªæ€§åŒ–çš„èƒ°å²›ç´ å‰‚é‡å»ºè®®ã€‚

**å…³é”®åˆ›æ–°**ï¼šABBAçš„ä¸»è¦åˆ›æ–°åœ¨äºå…¶åŸºäºå¼ºåŒ–å­¦ä¹ çš„ä¸ªæ€§åŒ–è°ƒæ•´æœºåˆ¶ï¼Œç›¸è¾ƒäºä¼ ç»Ÿçš„BBAï¼ŒABBAèƒ½å¤Ÿæ ¹æ®æ‚£è€…çš„å®æ—¶æ•°æ®åŠ¨æ€ä¼˜åŒ–èƒ°å²›ç´ å‰‚é‡ï¼Œä»è€Œæ˜¾è‘—æé«˜è¡€ç³–æ§åˆ¶çš„æ—¶é—´èŒƒå›´ã€‚

**å…³é”®è®¾è®¡**ï¼šåœ¨æŠ€æœ¯ç»†èŠ‚æ–¹é¢ï¼ŒABBAä½¿ç”¨äº†ç‰¹å®šçš„æŸå¤±å‡½æ•°æ¥ä¼˜åŒ–è¡€ç³–æ§åˆ¶ç›®æ ‡ï¼Œå¹¶è®¾è®¡äº†é€‚åº”æ€§çš„ç½‘ç»œç»“æ„ï¼Œä»¥ä¾¿æ›´å¥½åœ°å¤„ç†æ‚£è€…çš„ä¸ªæ€§åŒ–æ•°æ®ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

å®éªŒç»“æœæ˜¾ç¤ºï¼ŒABBAåœ¨æ¨¡æ‹Ÿæµ‹è¯•ä¸­æ˜¾è‘—æé«˜äº†è¡€ç³–æ§åˆ¶çš„æ—¶é—´èŒƒå›´ï¼ˆTIRï¼‰ï¼Œç›¸æ¯”äºæ ‡å‡†åŸºç¡€-æ³¢åŠ¨å‰‚é‡é¡¾é—®ï¼ˆBBAï¼‰ï¼ŒTIRçš„æå‡å¹…åº¦æ˜¾è‘—ï¼Œå¹¶ä¸”ABBAåœ¨ä¸¤ä¸ªæœˆå†…æŒç»­æ”¹å–„å…¶æ€§èƒ½ï¼Œè€ŒBBAä»…æœ‰å¾®å°å˜åŒ–ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶çš„æ½œåœ¨åº”ç”¨é¢†åŸŸåŒ…æ‹¬ç³–å°¿ç—…ç®¡ç†å’Œä¸ªæ€§åŒ–åŒ»ç–—ã€‚ABBAç³»ç»Ÿèƒ½å¤Ÿä¸º1å‹å’Œ2å‹ç³–å°¿ç—…æ‚£è€…æä¾›æ›´ä¸ºç²¾å‡†çš„èƒ°å²›ç´ è°ƒæ•´å»ºè®®ï¼Œä»è€Œä¼˜åŒ–è¡€ç³–æ§åˆ¶ï¼Œæå‡æ‚£è€…çš„ç”Ÿæ´»è´¨é‡ã€‚æœªæ¥ï¼ŒABBAæœ‰æœ›åœ¨ä¸´åºŠè¯•éªŒä¸­éªŒè¯å…¶æœ‰æ•ˆæ€§ï¼Œå¹¶æ¨å¹¿è‡³æ›´å¹¿æ³›çš„æ‚£è€…ç¾¤ä½“ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Despite recent advances in insulin preparations and technology, adjusting insulin remains an ongoing challenge for the majority of people with type 1 diabetes (T1D) and longstanding type 2 diabetes (T2D). In this study, we propose the Adaptive Basal-Bolus Advisor (ABBA), a personalised insulin treatment recommendation approach based on reinforcement learning for individuals with T1D and T2D, performing self-monitoring blood glucose measurements and multiple daily insulin injection therapy. We developed and evaluated the ability of ABBA to achieve better time-in-range (TIR) for individuals with T1D and T2D, compared to a standard basal-bolus advisor (BBA). The in-silico test was performed using an FDA-accepted population, including 101 simulated adults with T1D and 101 with T2D. An in-silico evaluation shows that ABBA significantly improved TIR and significantly reduced both times below- and above-range, compared to BBA. ABBA's performance continued to improve over two months, whereas BBA exhibited only modest changes. This personalised method for adjusting insulin has the potential to further optimise glycaemic control and support people with T1D and T2D in their daily self-management. Our results warrant ABBA to be trialed for the first time in humans.

